Last reviewed · How we verify

NCT07129811

Stellate Ganglion Block in Complex Regional Pain Syndrome

Recruiting now NA Last updated 5 September 2025
What this trial tests

NA trial testing Stellate Ganglion Block in Stellate Ganglion Block in 32 participants. Currently enrolling.

Timeline
15 January 2025
Primary endpoint
31 October 2025
31 October 2025

Quick facts

Lead sponsorAnkara City Hospital Bilkent
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment32
Start date15 January 2025
Primary completion31 October 2025
Estimated completion31 October 2025
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Ankara City Hospital Bilkent

Who can join

Adults 18 to 75, any sex, with Stellate Ganglion Block. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim was to investigate the effect of Stellate Ganglion Blockade, which will be applied in addition to conventional physical therapy, on pain and functionality in patients with poststroke complex regional pain syndrome.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Stellate Ganglion Block

Trials testing the same drug.

Other recruiting trials for Stellate Ganglion Block

Currently open trials in the same condition.

Other Ankara City Hospital Bilkent trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07129811.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing